İçeriğe geç
akaturk Akademik ölçüm
Giriş Kayıt

Akademisyen

ERDEM GÖKER

PROFESÖR

EGE ÜNİVERSİTESİ TIP FAKÜLTESİ DAHİLİ TIP BİLİMLERİ BÖLÜMÜ

Kayıtlı çıktılara kısa bakış — ayrıntılar aşağıda.

  • Makale 54
  • Proje 0
  • Kitap 1
  • Bildiri 0
  • Patent 0
  • Sanatsal 0
Scopus (SJR) Q1 21 Q2 14 Q3 4 Q4 5
WoS (JCR) Q1 10 Q2 11 Q3 14 Q4 7
TR Index 9 makale

Alan+yıl+tür normalize OpenAlex yüzdelik — Clarivate ESI / SciVal değildir.

Üst %1 makale 1
Üst %10 makale 9
Ort. yüzdelik 58.5%
Üst %1 payı 1.9%
Üst %10 payı 17.3%

Makaleler

YÖKSİS ve OpenAlex kaynak ayrımıyla makaleler; quartile ve TR Index ile daraltabilirsiniz.

Dizin filtreleri

Toplam 54 yayın

Scopus (SJR)
Q1 21 Q2 14 Q3 4 Q4 5
WoS (JCR)
Q1 10 Q2 11 Q3 14 Q4 7
TR Index
9 makale

Makale listesi

  1. 2026 Real-world outcomes of trastuzumab deruxtecan in patients with HER2+metastatic breast cancer: Turkish oncology group multicenter study THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY DOI 10.1177/17588359261430583 YÖKSİS SJR Q1 JCR Q2 OpenAlex üst %10 OpenAlex 91.3%
  2. 2026 Evaluation of the Independent Prognostic Role of Malnutrition in the Survival of Patients With Gastric Cancer Topics in Clinical Nutrition DOI 10.1097/TIN.0000000000000410 YÖKSİS SJR Q4 JCR Q4 OpenAlex 25.8%
  3. 2026 Folic acid-targeted chitosan-alginate blend nanoparticles for enhanced ixabepilone delivery and antitumor efficacy in breast cancer International Journal of Biological Macromolecules DOI 10.1016/j.ijbiomac.2026.151390 YÖKSİS SJR Q1 JCR Q1 OpenAlex 14.7%
  4. 2026 Folic acid-conjugated biopolymeric nanoparticles for targeted delivery of ixabepilone in breast cancer PREPARATIVE BIOCHEMISTRY & BIOTECHNOLOGY DOI 10.1080/10826068.2026.2621868 YÖKSİS SJR Q3 JCR Q3 OpenAlex 8.1%
  5. 2026 Prominent Lymphovascular Space Invasion as an Independent Prognostic Factor in LVSI-Positive Endometrioid Endometrial Carcinoma: Evidence for a Novel Three-Tiered Classification Journal of Clinical Medicine DOI 10.3390/jcm15093278 YÖKSİS SJR Q2 JCR Q1 OpenAlex 42.0%
  6. 2025 Efficacy and safety of doxorubicin–ifosfamide versus gemcitabine–docetaxel as first‐line therapy in advanced nonuterine leiomyosarcoma: A multicenter real‐world study International Journal of Cancer DOI 10.1002/ijc.70212 YÖKSİS SJR Q1 JCR Q2 OpenAlex 35.0%
  7. 2025 Real-world comparison of doxorubicin-ifosfamide versus gemcitabine-docetaxel regimens in metastatic uterine leiomyosarcoma: a multicenter retrospective study DISCOVER ONCOLOGY DOI 10.1007/s12672-025-03886-1 YÖKSİS SJR Q2 JCR Q3 OpenAlex 80.6%
  8. 2025 Regional and Gender-Based Distribution of KRAS Mutations in Metastatic Colorectal Cancer Patients in Turkey: An Observational Study Medicina DOI 10.3390/medicina61040694 YÖKSİS SJR Q2 JCR Q1 OpenAlex 81.0%
  9. 2025 Health-related quality of life and psychosocial outcomes in long-term survivors treated with immune checkpoint inhibitors: a nationwide multicenter study FRONTIERS IN IMMUNOLOGY DOI 10.3389/fimmu.2025.1693295 YÖKSİS SJR Q1 JCR Q1 OpenAlex 79.2%
  10. 2025 KRAS G12C Mutation Predicts Improved Survival in NSCLC Patients Receiving Immunotherapy: Insights from a Real-World Cohort journal of clinical medicine DOI 10.3390/jcm14196826 YÖKSİS SJR Q2 JCR Q1 OpenAlex 83.6%
  11. 2025 Ten-Year Real-World Outcomes and Clinicopathologic Predictors of Recurrence in Adult Granulosa Cell Tumors: A Turkish Single-Center Experience Current Oncology DOI 10.3390/curroncol32090504 YÖKSİS SJR Q2 JCR Q2 OpenAlex 22.3%
  12. 2025 Efficacy and Safety of the Topotecan–Cyclophosphamide Regimen in Adult Metastatic Ewing Sarcoma: A Large, Multicenter, Real-World Study CANCERS DOI 10.3390/cancers17030550 YÖKSİS SJR Q1 JCR Q2 OpenAlex 64.6%
  13. 2025 Real‐world effectiveness and safety of sacituzumab govitecan in patients with metastatic or unresectable locally advanced triple‐negative breast cancer: A multicenter study by the Turkish Oncology Group International Journal of Cancer DOI 10.1002/ijc.70213 YÖKSİS SJR Q1 JCR Q2 OpenAlex 68.3%
  14. 2025 Evaluation of implementation of evolving practice patterns in the first-line treatment of patients with metastatic non-small cell lung cancer in Turkiye (ESTIMATE): a national, multicenter, retrospective, real-world evidence study Future Oncology DOI 10.1080/14796694.2025.2527477 YÖKSİS SJR Q1 JCR Q2 OpenAlex 22.0%
  15. 2024 Caffeic acid phenethyl ester (CAPE) Chitosan capped ZnO nanoparticles: Preparation, characterization, and its potential for the treatment of prostate cancer Journal of Molecular Structure DOI 10.1016/j.molstruc.2024.138562 YÖKSİS SJR Q2 JCR Q2 OpenAlex üst %10 OpenAlex 90.3%
  16. 2024 Regorafenib Treatment for Recurrent Glioblastoma Beyond Bevacizumab-Based Therapy: A Large, Multicenter, Real-Life Study Cancers DOI 10.3390/cancers17010046 YÖKSİS SJR Q1 JCR Q2 OpenAlex üst %10 OpenAlex 92.2%
  17. 2024 PURE vs. mixed clear cell ovarian carcinomas: Is there any impact on survival? European Journal of Obstetrics & Gynecology and Reproductive Biology DOI 10.1016/j.ejogrb.2024.03.021 YÖKSİS SJR Q2 JCR Q2 OpenAlex 5.1%
  18. 2024 Cost of Hepatocellular Carcinoma from the Payer’s Perspective in Türkiye: Results of a Delphi Panel Analysis Global Journal of Medical and Pharmaceutical Sciences DOI 10.55640/gjmps/Volume03Issue09-03 YÖKSİS OpenAlex 21.4%
  19. 2023 Established and new treatment roadmaps for pleural mesothelioma: opinions of the Turkish Collaborative Group Current Problems in Cancer DOI 10.1016/j.currproblcancer.2023.101017 YÖKSİS SJR Q2 JCR Q3 OpenAlex 51.3%
  20. 2023 Real-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations: a Turkish Oncology Group (TOG) study Journal of Cancer Research and Clinical Oncology DOI 10.1007/s00432-022-03984-5 YÖKSİS SJR Q1 JCR Q3 OpenAlex 64.2%

Akademisyenlere dön